SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004506
Filing Date
2024-01-31
Accepted
2024-01-31 16:26:38
Documents
15
Period of Report
2024-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51652
2 ex2-3.htm EX-2.3 21374
  Complete submission text file 0001493152-24-004506.txt   251253

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20240130.xsd EX-101.SCH 3009
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20240130_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20240130_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3521
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 24583303
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)